Thymalin vs ARA-290: what the research actually compares
A comparison of the published research on Thymalin and ARA-290, covering what each compound is, what studies have measured, and where the evidence is stronger or simply absent.
Thymalin is a polypeptide complex derived from bovine thymus, classified as an immunomodulatory peptide. Its exact sequence and molecular weight are not specified in the evidence provided. Thymalin has been studied in experimental models of bone repair. ARA-290, also known as cibinetide, is a synthetic 11-amino acid peptide and an erythropoietin analogue that does not stimulate erythropoiesis. Its sequence and formula are not given in the evidence. ARA-290 is studied primarily as an innate repair receptor (IRR) agonist.
The work on ARA-290 centres on the innate repair receptor, a heteromeric complex of the erythropoietin receptor and the beta-common receptor. Thymalin’s reported activity involves modulation of T-lymphocytes, B-lymphocytes, and macrophages, though the specific receptor or pathway is not detailed in the evidence.
Research Studies
Thymalin and T-lymphocyte, B-lymphocyte, and macrophage expression in rat mandible regenerate
A study in rats examined the expression of T-lymphocytes, B-lymphocytes, and macrophages in the post-traumatic regenerate of the mandible after filling a bone defect with a hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with Thymalin [5]. The study reported on the features of immune cell expression in this model. The findings are specific to the rat mandible and the described surgical intervention.
Thymalin and reparative osteogenesis in rat mandible
A separate experimental and morphological study in rats investigated reparative osteogenesis in the lower jaw bone when a bone defect was filled with a hydroxyapatite-containing osteotropic material (bone graft "Biomin GT") and the surrounding soft tissues were injected with Thymalin [6]. The study aimed to identify morphological features of bone repair under these conditions. The results pertain to the rat model and the combined use of the graft material and Thymalin.
Thymalin in regenerative medicine reviews
A narrative review of peptides in regenerative medicine for tissue repair and chronic pain management included Thymalin among other peptides such as BPC-157, thymosin beta-4, and GHK-Cu [7]. The review summarises evidence on regenerative peptides but does not present primary data on Thymalin. It provides context for the broader field but does not constitute direct evidence of efficacy for Thymalin.
ARA-290 and diabetic macular oedema
A phase II clinical trial (NCT06626971) investigated ARA-290 in patients with type 1 or type 2 diabetes and diabetic macular oedema (DMO) [1]. The primary objective was to determine whether ARA-290 administered at a daily dose of 4 mg subcutaneously for 12 weeks would affect the mean change in best corrected visual acuity (BCVA) from baseline to week 12. The trial was prospective, open label, interventional, single centre, and investigator led. The outcome measures focused on visual acuity changes in this population.
ARA-290 and corneal nerve fiber density in sarcoidosis
A study (NCT02039687) evaluated ARA-290 in subjects with sarcoidosis and symptoms of small fiber neuropathy [2]. The purpose was to determine whether ARA-290 is effective in treating neuropathic symptoms of sarcoidosis. The study description notes that brief interaction of ARA-290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory activities in various cells, tissues, and organs, activating repair mechanisms and accelerating healing, including nerve damage associated with sarcoidosis. Subjects received ARA-290 or placebo by subcutaneous injection daily for 28 days. Safety and symptoms of small fiber neuropathy were monitored.
ARA-290 and glucose levels in prediabetes and type 2 diabetes
A study (NCT01933529) examined whether ARA-290, a non-hematopoietic erythropoietin analogue, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose tolerance or impaired fasting glucose) or drug-naive type 2 diabetes [3]. The study also evaluated effects on insulin sensitivity and serum levels of inflammatory agents such as cytokines. Safety was monitored through hematology, kidney and liver function, and lipid levels. The population was specifically those with prediabetes or early type 2 diabetes not yet on medication.
ARA-290 and cognitive and neural processing of emotions in healthy volunteers
A study (NCT02070783) investigated the effects of ARA-290 on cognitive and neural processing of emotions in healthy volunteers [4]. The rationale was based on studies of erythropoietin (EPO) suggesting antidepressant properties, but EPO may cause serious side-effects with repeated administration (thrombosis), limiting its usefulness. ARA-290 is a peptide that does not have EPO’s effects on blood cells but may still affect brain function. The study hypothesised that a single dose of ARA-290 would lead to a positive shift in information processing compared to placebo, 7 days post-administration. The population was healthy volunteers, and the outcome was cognitive and neural processing of emotions.
Comparison of evidence across compounds
The table below summarises the key features of the studies identified for each compound.
| Compound | Study type | Population/model | Intervention | Primary outcome/aim |
|---|---|---|---|---|
| Thymalin | Experimental animal study [5] | Rats, mandible bone defect | Hydroxyapatite material + Thymalin injection | T-lymphocyte, B-lymphocyte, macrophage expression |
| Thymalin | Experimental morphological study [6] | Rats, mandible bone defect | Biomin GT + Thymalin injection | Reparative osteogenesis features |
| Thymalin | Narrative review [7] | Various (not primary) | Not applicable | Summary of regenerative peptides |
| ARA-290 | Phase II clinical trial [1] | Humans with type 1/2 diabetes and DMO | 4 mg subcutaneous daily for 12 weeks | Mean change in BCVA |
| ARA-290 | Clinical trial [2] | Humans with sarcoidosis and small fiber neuropathy | Subcutaneous daily for 28 days | Neuropathic symptoms, safety |
| ARA-290 | Clinical trial [3] | Humans with prediabetes or drug-naive T2D | Not specified in evidence | Blood glucose, insulin secretion, insulin sensitivity, cytokines |
| ARA-290 | Clinical trial [4] | Healthy volunteers | Single dose | Cognitive and neural processing of emotions |
Where the evidence is stronger for one compound
The evidence for ARA-290 includes multiple registered clinical trials in human populations, with specified doses, routes, and durations [1][2][3][4]. These studies address conditions such as diabetic macular oedema, sarcoidosis-associated small fiber neuropathy, prediabetes and type 2 diabetes, and cognitive processing in healthy volunteers. The evidence for Thymalin is limited to experimental studies in rats and a narrative review that mentions it among other peptides [5][6][7]. No human clinical trials of Thymalin are described in the evidence provided. Therefore, the published work on ARA-290 is more extensive in terms of human data and clinical endpoints, while Thymalin’s evidence is confined to preclinical models and secondary mentions.
What is simply not known
For Thymalin, the evidence does not provide information on its exact sequence, molecular weight, or specific receptor targets. Its effects in humans are not documented in the provided studies. The long-term safety, optimal dose, and clinical efficacy in any human condition remain unknown from the evidence. For ARA-290, while clinical trials exist, the evidence block does not report the results or outcomes of these trials; it only describes their objectives and designs. Therefore, whether ARA-290 achieved its primary endpoints in these studies is not stated. Comparative studies directly evaluating Thymalin versus ARA-290 are absent. The mechanisms of action for both compounds are not fully elucidated in the evidence, and no head-to-head data exist to suggest superiority of one over the other for any indication.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The Use of ARA290 for the Treatment of Diabetic Macular Oedema
- [2] Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
- [3] ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
- [4] Cognitive and Neural Effects of ARA290
- [5] Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues.
- [6] Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.
- [7] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.